VITAL-H: Validation and Intervention Testing for Aging, Longevity and Healthspan

The team will establish a regulatory path for testing the efficacy of therapeutics for aging by conducting a phase 3 hybrid trial to repurpose three FDA-approved drugs: SGLT2 inhibitor, rapamycin, and semaglutide.  

Back to Award Directory